NCT03061188: Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes

NCT03061188
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients with certain mutations will be eligible for expansion cohorts- see trial for details
Exclusions: Unstable brain metastases requiring treatment
https://ClinicalTrials.gov/show/NCT03061188

Comments are closed.

Up ↑